Innovations in artificial intelligence are driving breakthroughs in cancer diagnostics, drug discovery, and clinical trial optimization. Imagene AI secured $23 million in Series B funding to advance its multi-modal pathology foundation models, integrating histological and molecular data. Additionally, Pfizer has expanded its molecular modeling collaboration with XtalPi, leveraging AI for small-molecule drug design. These developments underscore AI’s role in accelerating personalized medicine, improving prognosis prediction, and streamlining drug development pipelines in oncology.